Article Text

other Versions

PDF
Paediatric pharmacogenomics: an overview
  1. Daniel B Hawcutt1,2,
  2. Ben Thompson1,2,
  3. Rosalind L Smyth3,
  4. Munir Pirmohamed2
  1. 1Division of Developmental and Reproductive Medicine, Women's and Children's Health, University of Liverpool, Liverpool, Merseyside, UK
  2. 2Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, Merseyside, UK
  3. 3Professor of Child Health, UCL Institute of Child Health, London, UK
  1. Correspondence to Dr Dan B Hawcutt, Division of Developmental and Reproductive Medicine, Women's and Children's Health, University of Liverpool, Alder Hey Children's Hospital, Eaton Road, Liverpool L12 2AP, UK; d.hawcutt{at}liverpool.ac.uk.

Abstract

Pharmacogenomics research is becoming more prevalent in both academia and the pharmaceutical industry. While some discoveries have been integrated into practice and are benefiting patient care, these successes have been limited given the vast amount of research undertaken. However, the advances in high-throughput genomic technologies, better study designs and improved understanding of complexity, means that pharmacogenomic determinants of drug response will continue to be identified. It is important to develop an understanding of the basis of pharmacogenomics in clinical teams to allow accurate interpretation of the findings, and facilitate their implementation into clinical care (if appropriate). This article explains the science behind pharmacogenomics, and describes some of the challenges that have been encountered in the field, with a specific focus on paediatrics.

  • Pharmacology
  • Genetics
  • Paediatrics
  • Toxicology
  • Basic Science

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.